Table 1.
Baseline patient characteristics according to induction regimens.
| Variable | VAD (n = 31) | TD (n = 31) | CTD (n = 19) | p-value |
|---|---|---|---|---|
| Mean age - years | 52 | 55 | 58 | 0.05 |
| Gender -n | 0.45 | |||
| Male | 19 | 14 | 12 | |
| Female | 20 | 17 | 7 | |
| DSSa - n | 0.46 | |||
| I | 1 | 0 | 0 | |
| II | 2 | 5 | 2 | |
| III | 36 | 25 | 17 | |
| ISSa - n | 0.29 | |||
| I | 11 | 6 | 4 | |
| II | 17 | 9 | 3 | |
| III | 7 | 6 | 7 | |
| Plasmocytoma - n | 0.97 | |||
| Yes | 5 | 5 | 4 | |
| No | 19 | 15 | 15 | |
| Number of cycles -n | n | 0.01 | ||
| < 4 | 21 | 10 | 4 | |
| ≥ 4 | 17 | 16 | 15 | |
| Median follow up - monthsa | 32.2 | 14.2 | 5.5 | < 0.01 |
VAD: vincristine, doxorubicin and dexamethasone; TD: thalidomide and dexamethasone; CTD: cyclophosphamide, thalidomide and dexamethasone; DSS: Durie-Salmon staging system; ISS: International Staging System.
a
Data were missing for one patient regarding DSS, 19 patients regarding ISS (from lack of beta-2-microglobulin levels), six patients regarding the number of cycles, and 11 patients regarding follow-up.